CHRS Coherus BioSciences Inc

Price (delayed)

$7.5

Market cap

$580.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.72

Enterprise value

$681.97M

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings ...

Highlights
The net income has plunged by 176% YoY but it is up by 27% from the previous quarter
Coherus BioSciences's EPS has shrunk by 167% YoY but it has increased by 29% QoQ
The equity has plunged by 90% YoY and by 87% from the previous quarter
The gross profit has contracted by 40% YoY and by 9% from the previous quarter

Key stats

What are the main financial stats of CHRS
Market
Shares outstanding
77.42M
Market cap
$580.67M
Enterprise value
$681.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
46.13
Price to sales (P/S)
1.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.25
Earnings
Revenue
$303.63M
EBIT
-$183.96M
EBITDA
-$178.9M
Free cash flow
-$94.6M
Per share
EPS
-$2.72
Free cash flow per share
-$1.22
Book value per share
$0.16
Revenue per share
$3.93
TBVPS
$7.63
Balance sheet
Total assets
$593.39M
Total liabilities
$580.82M
Debt
$426.97M
Equity
$12.56M
Working capital
$358.7M
Liquidity
Debt to equity
33.99
Current ratio
3.33
Quick ratio
2.88
Net debt/EBITDA
-0.57
Margins
EBITDA margin
-58.9%
Gross margin
80.4%
Net margin
-69.2%
Operating margin
-58.4%
Efficiency
Return on assets
-30.5%
Return on equity
-211.7%
Return on invested capital
-35.9%
Return on capital employed
-41.8%
Return on sales
-60.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CHRS stock price

How has the Coherus BioSciences stock price performed over time
Intraday
1.49%
1 week
19.05%
1 month
-2.22%
1 year
-50.69%
YTD
-53.01%
QTD
-41.91%

Financial performance

How have Coherus BioSciences's revenue and profit performed over time
Revenue
$303.63M
Gross profit
$244.18M
Operating income
-$177.42M
Net income
-$210.24M
Gross margin
80.4%
Net margin
-69.2%
The net income has plunged by 176% YoY but it is up by 27% from the previous quarter
The gross profit has contracted by 40% YoY and by 9% from the previous quarter
The operating income has grown by 33% from the previous quarter
The revenue has declined by 31% year-on-year and by 7% since the previous quarter

Growth

What is Coherus BioSciences's growth rate over time

Valuation

What is Coherus BioSciences stock price valuation
P/E
N/A
P/B
46.13
P/S
1.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.25
Coherus BioSciences's EPS has shrunk by 167% YoY but it has increased by 29% QoQ
The price to book (P/B) is 123% more than the 5-year quarterly average of 20.7 and 71% more than the last 4 quarters average of 27.0
The equity has plunged by 90% YoY and by 87% from the previous quarter
The P/S is 97% below the 5-year quarterly average of 68.0 and 42% below the last 4 quarters average of 3.3
The revenue has declined by 31% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is Coherus BioSciences business performance
CHRS's return on invested capital is up by 29% since the previous quarter
Coherus BioSciences's return on sales has increased by 25% QoQ
The return on assets is up by 24% since the previous quarter
CHRS's return on equity is up by 6% since the previous quarter

Dividends

What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CHRS.

Financial health

How did Coherus BioSciences financials performed over time
The total assets is 2.2% more than the total liabilities
The current ratio has grown by 39% YoY but it has contracted by 9% from the previous quarter
Coherus BioSciences's quick ratio has increased by 37% YoY but it has decreased by 12% QoQ
The equity has plunged by 90% YoY and by 87% from the previous quarter
The debt has grown by 3.1% year-on-year and by 2.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.